Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.36 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25748806 | 1.00 | HDAC6 (0.41) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL25100482 | 0.89 | SMN1; SMN2 (0.41) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL25964475 | 0.88 | SMN1; SMN2 (0.44) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL20169738 | 0.85 | HDAC3 (0.36) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL22064399 | 0.85 | HDAC3 (0.36) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL23680206 | 0.85 | SMN1; SMN2 (0.43) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL25869906 | 0.85 | HDAC1 (0.40) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL25748810 | 0.84 | OPRL1 (0.41) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL27442287 | 0.83 | HDAC3 (0.34) | HDAC6HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL18389703 | 0.83 | HDAC3 (0.40) | HDAC6HDAC1HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141575-A1 | ANTIBODY-DRUG CONJUGATES TARGETING UPARAP COMPRISING EXATECAN DERIVATIVES | ADCENDO APS (DK) | 2024-07-04 | — | — | WO | disclosed |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | HDAC6 1861/4885HDAC1 2112/4885HDAC4 2463/4885 |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | HDAC6 1861/4885HDAC1 2112/4885HDAC4 2463/4885 |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | HDAC6 1861/4885HDAC1 2112/4885HDAC4 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.